Mesoblast reveals more COVID trials needed, shares tumble smh.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from smh.com.au Daily Mail and Mail on Sunday newspapers.
Mesoblast (MESO) Q3 2021 Earnings Call Transcript fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
Nachrichtenquelle: globenewswire | 01.07.2021, 01:46 | 103 | 0 NEW YORK, June 30, 2021 (GLOBE NEWSWIRE) Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the strategy for bringing rexlemestrocel-L to patients in the United States (US) with chronic low back pain (CLBP) due to degenerative disc disease (DDD) refractory to available therapies, including opioids. Excessive use of opioids in this patient population continues to be a major focus for US healthcare policymakers, regulatory authorities, patients and physicians, with more than 50% of US opioid prescriptions being for the treatment of CLBP.
1,6,7 Mesoblast has filed a request and expects to hold a Type C meeting with the US Food & Drug Administration (FDA) during the current quarter to disc
Mesoblast Provides Update on Program for Chronic Low Back globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ACHL) - The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.